EyePoint (EYPT) Long-Term Deferred Tax (2017 - 2018)
EyePoint (EYPT) posted Long-Term Deferred Tax of $6.2 million for Q2 2018, down 71.16% sequentially from $21.5 million in Q4 2017, and down 80.32% YoY from $31.5 million in Q2 2017.
Powered by 
Analysis
EyePoint (EYPT) Long-Term Deferred Tax (2017 - 2018) Analysis & Trends
EyePoint has reported Long-Term Deferred Tax for 2 years, with the latest figure at $6.2 million in Q2 2018.
- Quarterly Long-Term Deferred Tax fell 80.32% year-over-year to $6.2 million in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $6.2 million (down 80.32% YoY) and the FY2018 annual result came in at $6.2 million, down 80.32% from the prior year.
- Long-Term Deferred Tax eased to $6.2 million in Q2 2018 per EYPT's latest filing, from $21.5 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $31.5 million in Q2 2017 and troughed at $6.2 million in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2018 | 6.20 Mn |
| Dec 31, 2017 | 21.50 Mn |
| Jun 30, 2017 | 31.50 Mn |